Skip to main content
SpringerLink
Log in

Perspectives of surgery and multimodality treatment in gastric carcinoma

  • Guest Editorial
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Surgery still represents the therapy of choice for patients with primary gastric adenocarcinoma. The best survival results can be achieved if a potentially curative (R0) resection can be performed whatever the extent of resection of the primary tumor (total versus subtotal distal gastrectomy). Either procedure should be accompanied by systematic lymph node dissection since lymphadenectomy has relevant diagnostic (i.e. staging) and therapeutic implications (i.e. improved survival in stage II/IIIA disease). Since most gastric carcinomas are diagnosed in advanced tumor stages, the number of patients to be treated curatively by surgery alone remains limited. Multimodality treatment, consisting of chemotherapy and surgery, may be an encouraging alternative strategy. With actual chemotherapy protocols (i.e. 5-FU/doxorubicin/methotrexate, etoposide/doxorubicin/cisplatin) high remission rates in locally advanced irresectable lesions without distant metastases can be induced. Survival in these patients has been significantly improved after chemotherapy and second-look surgery. The effectiveness of these protocols in an adjuvant setting seems a worthwhile study for the future. In addition, immunological and somatic gene therapy may be of therapeutic impact in the next decade.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Abe M, Yabumoto E, Takahashi M, Adachi H, Yoshi M, Mori K (1981) Intraoperative radiotherapy of gastric cancer. Cancer 45:40–44

    Google Scholar 

  • Abe M, Takahashi M, Shibamoto Y, Ono K, Yabumoto E, Mori K (1988) Derzeitige Stellung der intraoperativen Chemotherapie. Chirurg 59:211–217

    Google Scholar 

  • Adam YG, Efron G (1989) Trends and controversies in the management of carcinoma of the stomach. Surg Gynecol Obstet 169:371–385

    Google Scholar 

  • Ajani JA, Ota DM, Jessup JM, Ames FC, McBride C, Boddie A, Levin B, Jackson DE, Roh M, Hohn D (1991) Resectable gastric carcinoma — an evaluation of preoperative and postoperative chemotherapy. Cancer 68:1501–1506

    Google Scholar 

  • Allum WH, Powell DJ, McConkey CC, Fielding JWL (1989a) Gastric cancer: a 25-year review. Br J Surg 76:535–540

    Google Scholar 

  • Allum WH, Hallissey MT, Kelly KA for the British Stomach Cancer Group (1989b) Adjuvant chemotherapy in operable gastric cancer. Lancet I:571–574

    Google Scholar 

  • Baba T, Nakane Y, Okusa T, Hirozane N, Imabayashi N, Hioki K, Yamamoto M (1989) Strategy for lymphadenectomy of gastric cancer. Surgery 105:585–592

    Google Scholar 

  • Blot WJ, Devesa SS, Kneller RW, Fraumeni JF (1991) Rising incidence of adenocarcinoma of the esiphagus and gastric cardia. JAMA 265:1287–1289

    Google Scholar 

  • Boring CC, Squires TS, Tong T (1991) Cancer statistics, 1991. CA 41:19–36

    Google Scholar 

  • Brady MS, Ragatko A, Dent LL, Shiu MH (1991) Effect of splenectomy on morbidity and survival following curative gastrectomy for carcinoma. Arch Surg 126:359–364

    Google Scholar 

  • Candela FC, Urmacher C, Brennan MF (1990) Comparison of the conventional method of lymph node staging with a comprehensive fatclearing method for gastric adenocarcinoma. Cancer 66:1828–1832

    Google Scholar 

  • Dent DM, Madden MV, Price SK (1988) Randomized comparison of R2-gastrectomy for gastric carcinoma. Br J Surg 75:110–112

    Google Scholar 

  • Diehl JT, Herman RE, Cooperman AM, Hoerr SO (1983) Gastric carcinoma. A ten year review. Ann Surg 198:9–12

    Google Scholar 

  • Findlay M, Mansi JL, Ford HT, Nash AT, Cunningham D (1991) Epirubicin, cisplatin and 5-fluorouracil (ECF) is highly effective in advanced gastric cancer. Eur J Cancer [Suppl] 2:71 (abstr)

    Google Scholar 

  • Fujimoto S, Akao T, Itol B, Koshizuka I, Koyano K (1976) A study of survival in patients with stomach cancer treated by a combination of preoperative intra-arterial infusion therapy and surgery. Cancer 37:1648–1654

    Google Scholar 

  • Gall FP, Hermanek P (1985) New aspects in the surgical treatment of gastric carcinoma: a comparative study of 1636 patients operated on between 1969 and 1982. Eur J Surg Oncol 11:219–225

    Google Scholar 

  • Gall FP, Hermanek P (1988) Die erweiterte Lymphknotendissektion beim Magen — und colorektalen Carcinom — Nutzen und Risiken. Chirurg 59:202–210

    Google Scholar 

  • Gastrointestinal Tumor Study Group (1982a) Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. Cancer 49:1116–1122

    Google Scholar 

  • Gastrointestinal Tumor Study Group (1982b) A combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma. Cancer 49:1771–1777

    Google Scholar 

  • Gennari L, Bozzetti F, Bonfanti G, Morabito A, Bufalino R, Doci R, Andreola S (1986) Subtotal versus total gastrectomy for cancer of the lower two-thirds of the stomach: a new approach to an old problem. Br J Surg 73:534b-538

    Google Scholar 

  • Gouzi JL, Huguier M, Fagniez PL, Launois B, Flamant Y, Lacaine F, Paquet JC, Hay JM (1989) Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. Ann Surg 209:162–167

    Google Scholar 

  • Guillou PJ, Monson JRT (1989) Immunological contributions to the management of gastric cancer. Hepatogastroenterology 36:86–91

    Google Scholar 

  • Haim N, Robinson E (1991) Combination of etoposide, adriamycin and cisplatin (EAP) in gastric cancer: Association with severe toxicity. Ann Oncol 2:311–312

    Google Scholar 

  • Haugstvedt T, Viste A, Eide GE, Söreide O, Members of the Norwegian Stomach Cancer Trial (1989) The survival benefit of resection in patients with advanced stomach cancer: The Norwegian multicenter experience. World J Surg 13:617–622

    Google Scholar 

  • Heberer G, Teichmann RK, Krämling HJ, Günther B (1988) Results of gastric resection for carcinoma of the stomach: the European experience. World J Surg 12:374–381

    Google Scholar 

  • Hermanek P (1989) Magenkarzinom — Präkanzerosen, Klassifikation and Prognose. In: Hotz, J, Meyer HJ, Schmoll HJ (eds) Magenkarzinom Springer, Berlin Heidelberg New York, pp 16–27

    Google Scholar 

  • Hirohashi S, Sugimura T (1991) Genetic alterations in human gastric cancer. Cancer Cells 3:49–52

    Google Scholar 

  • Hisamichi S (1989) Screening for gastric cancer. World J Surg 13:31–37, 1989

    Google Scholar 

  • Hoel DG, Davis DL, Miller AB, Sondik EJ, Swerdlow AJ (1992) Trends in cancer mortality in 15 industrialized countries, 1969–1986. JNCI 84:313–320

    Google Scholar 

  • Iaffaioli RV, Frasci G, Facchini G, Tortoriello A, Persico G, Canove G, Bianco AR (1991) Neoadjuvant immunochemotherapy (FEP-IFN) in locally advanced gastric cancer. Preliminary data (abstract). Eur J Oncol [Suppl] 2:77

    Google Scholar 

  • Irvin TT, Bridger JE (1988) Gastric cancer: an audit of 122 consecutive cases and the results of R1 gastrectomy. Br J Surg 75:106–109

    Google Scholar 

  • Jaehne J, Meyer HJ, Maschek H, Geerlings H, Bruns E, Pichlmayr R (1992a) Lymphadenectomy in gastric carcinoma — a prospective and prognostic study. Arch Surg 127:290–294

    Google Scholar 

  • Jaehne J, Urmacher C, Thaler HT, Friedlander-Klar H, Cordon-Cardo C, Meyer HJ (1992b) Expression ofHer2/neu oncogene product p185 in correlation to clinicopathological and prognostic factors of gastric carcinoma. J Cancer Res Clin Oncol 118:474–479

    Google Scholar 

  • Jaehne J, Urmacher C, Cordon-Cardo C, Meyer HJ, Pichlmayr R (1993) DNA-Analyse bein Magenkarzinom-Korrelation von Anenploidie mit der Tumorlokalisation: Chirung (in press)

  • Jamieson JK, Dobson JF (1907) The lymphatic system of the stomach. Lancet I:1061–1066

    Google Scholar 

  • Japanese Research Society for Gastric Cancer (1981) The general rules for the gastric cancer study in surgery and pathology. Jpn J Surg 11:127–139

    Google Scholar 

  • Kampschöer GHM, Nakajima T, Velde CJH, van de (1989) Changing pattens in gastric adenocarcinoma. Br J Surg 76:914–916

    Google Scholar 

  • Katz A, Gansl RC, Simon SD, Gama-Rodrigues J, Waitzberg D, Bresciani CJ, Pinotti HW (1991) Phase II trial of etoposide (V), adriamycin (A), and cisplatinum (P) in patients with metastatic gastric cancer. Am J Clin Oncol 14:357–358

    Google Scholar 

  • Kelsen D, Atiq OT, Saltz L, Niedzwiecki D, Ginn D, Chapman D, Heelan R, Lightdale C, Vinviguerra, Brennan M (1992) FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 10:541–548

    Google Scholar 

  • Kim BS, Chung CH, Roh JK, Park YJ, Koh EH, Kim JH, Min JS, Lee KS, Lee KB, Youn JK (1991) A controlled trial of 5-FU, doxorubicin (FA) chemotherapy vs FA-polyadenylic, polyuridylic acid (poly-AU) chemoimmunotherapy for locally advanced gastric cancer after curative resection: an interim report (abstract). Proc Am Soc Clin Oncol 10:134

    Google Scholar 

  • Kim JP (1991) Immunochemosurgery (postoperative immunochemotherapy) as a reasonable treatment of stage III gastric carcinoma. Onkologie 14:148–151

    Google Scholar 

  • Kim NK, Park YS, Suh CI, Kan WK, Kim HT, Heo DS, Bang YJ (1991) Phase III randomized comparison of 5-FU vs FAM (5-FU/AD-RIA/MMC) vs FP (5-FU/cisplatin) in patients with advanced gastric carcinoma (AGC) (abstract). Proc Am Soc Clin Oncol 10:144

    Google Scholar 

  • Kim SY, Song MH, Park CS, Lee HY, Kim YK, Lee BH, An BJ (1989) Etoposide, adriamycin, and cisplatin (EAP) combination chemotherapy for advanced gastric cancer (abstract). Blut 59:257; 51

    Google Scholar 

  • Klein IIO, Wickramanayake PD, Farrokh GH (1986) 5-Fluorouracil (%-FU), Adriamycin (ADM) and methotrexate (MTX) — a combination protocol (FAMTX) for treatment of metastasized stomach cancer (abstract). Proc Am Soc Clin Oncol 5:84

    Google Scholar 

  • Kodama Y, Sugimachi K, Soejima K, Matsusaka T, Inokuchi K (1981) Evaluation of extensive lymph node dissection for carcinoma of the stomach. World J Surg 5:241–248

    Google Scholar 

  • Korenaga D, Moriguchi S, Orita H, Kakeji Y, Haraguchi M, Maehara Y, Sugimachi K (1992) Trends in survival rates in Japanese patients with advanced carcinoma of the stomach. Surg Gynecol Obstet 174:387–393

    Google Scholar 

  • Laurén P (1965) The two histological main types of gastric carcinoma — diffuse and so-called intestinal type carcinoma. Acta Pathol Microbiol Scand 64:31–49

    Google Scholar 

  • Leichman L, Silberman H, Leichman C, Laine L, Ramos H, Spears P, Jeffers S (1990) Neoadjuvant chemotherapy for gastric adenocarcinoma followed by postoperative intraperitoneal (IP) chemotherapy (abstract). Proc Am Soc Clin Oncol 9:109

    Google Scholar 

  • Lindahl AK, Harbitz TB, Liavag I (1988) The surgical treatment of gastric cancer: a retrospective study with special reference to total gastrectomy. Eur J Surg Oncol 14:55–62

    Google Scholar 

  • Mahjoubi M, Rougier P, Oliviera J, Tigaud JM, Bognel C, Lasser P, Droz JP (1990) Phase II trial of combined 5-FU+CDDP in gastric cancer (GC) (abstract). J Cancer Res Clin Oncol [Suppl 1] 116:677

    Google Scholar 

  • Maruyama K, Okabayashi K, Kinoshita T (1987) Progress in gastric cancer surgery in Japan and its limits to radicality. World J Surg 11:418–425, 1987

    Google Scholar 

  • McNeer G, Sunderland DA, McInnes G, Vandenberg H, Lawrence W (1951) A more thorough operation for gastric cancer: anatomical basis and description of technique. Cancer 4:957–967

    Google Scholar 

  • McNeer G, Bowden L, Booher RJ, McPeak CJ (1974) Elective total gastrectomy for cancer of the stomach: end results. Ann Surg 180:252–256

    Google Scholar 

  • Meyer HJ, Pichlmayr R (1987) Pattern of recurrence to therapeutic strategy in gastric cancer. Scand J Gastroenterol 22:45–48

    Google Scholar 

  • Meyer HJ, Jachne J, Pichlmayr R (1989) Surgical treatment of gastric carcinoma: a retrospective analysis with special regard to the value of total gastrectomy as the operation of choice. J R Coll Surg Edinb 34:258–262

    Google Scholar 

  • Meyer HJ, Jaehne J, Wilke H, Pichlmayr R (1991) Surgical treatment of gastric cancer: retrospective survey of 1704 operated cases with special reference to total gastrectomy as the operation of choice. Semin Surg Oncol 7:356–364

    Google Scholar 

  • Miholic J, Meyer HJ, Kotzerke J, Balks J, Aebert H, Jaehne J, Weimann A, Pichlmayr R (1989) Emptying of the gastric substitute after total gastrectomy: jejunal interposition vs Roux — Y esophago-jejunostomy. Ann Surg 210:165–172

    Google Scholar 

  • Mishima Y, Hirayama R (1987) The role of lymph node surgery in gastric cancer. World J Surg 11:406–411

    Google Scholar 

  • Moriguchi S, Machara Y, Korenaga D, Sugimachi K, Hayashi Y, Nose Y (1992) Prediction of survival time after curative surgery for advanced gastric cancer. Eur J Surg Oncol 18:287–292

    Google Scholar 

  • Nakajima T, Nishi M (1989) Surgery and adjuvant chemotherapy for gastric cancer. Hepatogastroenterology 36:79–85

    Google Scholar 

  • Nielsen J, Aagaard J, Toftgaard C (1985) Gastric cancer with special reference to prognostic factors. Acta Chir Scand 151:49–55

    Google Scholar 

  • Papachristou DN, Fortner JG (1981) Local recurrence of gastric adenocarcinomas after gastrectomy. J Surg Oncol 18:47–53

    Google Scholar 

  • Parkin DM, Läärä E, Muir CS (1988) Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer 41:184–197

    Google Scholar 

  • Pichlmayr R, Meyer HJ (1988) Indications for total gastrectomy. Nutrition 4:165–168

    Google Scholar 

  • Plukker JTM, Kampschöer GHM (1990) Extended lymph-node dissection for gastric cancer: a challenge for better survival results. Neth J Surg 42:3–8

    Google Scholar 

  • Preusser P, Achterrath W, Wilke H, Lenaz L, Fink U, Heinicke H, Meyer J, Bünte H (1988) Chemotherapy of gastric cancer. Cancer Treat Rev 15:257–277

    Google Scholar 

  • Raeth U, Flechtner H, Selbach J, Harjung H, Manegold C, Kabelitz K, Trux FA, Edler L, Schlag P, Queißer W (1990) Etoposide, Adriamycin, and cisplatinum (EAP) combination chemotherapy for advanced gastric cancer. Onkologie 13:194–197

    Google Scholar 

  • Rhode H, Gebbensleben B, Bauer P, Stützer H, Zieschang J (1989) Has there been any improvement in the staging of gastric cancer? Cancer 64:2465–2481

    Google Scholar 

  • Roukos DH, Hottenrott C, Lorenz M, Koutsogiorgas-Couchell S (1990) A critical evaluation of effectivity of extended lymphadenectomy in patients with carcinoma of the stomach. J Cancer Res Clin Oncol 116:307–313

    Google Scholar 

  • Schmitz-Moormann P, Thomas C, Pohl C, Soehl R (1982) Patho — anatomical demonstration of lymph node metastases in a surgical specimen. Pathol Res Pract 174:403–411

    Google Scholar 

  • Secco GB, Fardelli R, Campora E, Rovida S, Percivale PL (1988) Factors influencing survival in 242 cases of primary gastric carcinoma. J Surg Oncol 38:10–13

    Google Scholar 

  • Shiu MH, Moore E, Sanders M, Huvos A, Freedman B, Goodbold J, Chaiyaphruk S, Wesdorp R, Brennan MF (1987) Influence of the extent of resection on survival after curative treatment of gastric carcinoma. Arch Surg 122:1347–1351

    Google Scholar 

  • Shiu MH, Perotti M, Brennan MF (1989) Adenocarcinoma of the stomach: a multivariate analysis of clinical, pathologic and treatment factors. Hepatogastroenterology 36:7–12

    Google Scholar 

  • Siewert JR (1991) Lymphadenektomie beim Magenkarzinom? Chirurg 62:881–884

    Google Scholar 

  • Siewert JR, Iange J, Böttcher K, Hölscher M, Weiser HF, Gössner W (1987) Magenkarzinom — Bestandsaufnahme aus chirurgischer Sicht Dtsch Med Wochenschr 112:622–628

    Google Scholar 

  • Siewert JR, Böttcher K, Busch R, Hermanek P, Meyer HJ, Roder JD (1992) Prognostic relevance of systematic lymph node dissection: results of the German gastric carcinoma study. Br J Surg (in press)

  • Smith JW, Shiu MH, Kelsey L, Brennan MF (1991) Morbidity of radical lymphadenectomy in the curative resection of gastric carcinoma. Arch Surg 126:1469–1473

    Google Scholar 

  • Soga J, Ohyama S, Miyashita K, Suzuki T, Nashimoto A, Tanaka O (1988) A statistical evaluation of advancement in gastric cancer surgery with special reference to the significance of lymphadenectomy for cure. World J Surg 12:398–405

    Google Scholar 

  • Stahl M, Wilke H, Preusser P, Fink U, Achterrath W, Schöber C, Köhne-Wömpner CH, Harstrick A, Meyer HJ, Meyer J, Lenaz, L, Schmoll HJ (1991) Etoposide, leukovorin and 5-fluorouracil (ELF) in advanced gastric carcinoma — final results of a phase-II study in elderly patients or patients with cardia risk. Onkologie 14:314–318

    Google Scholar 

  • Stephens FO (1988) Management of gastric cancer with regional chemotherapy proceding gastrectomy — 5-year survival results. Reg Cancer Treat 1:80–82

    Google Scholar 

  • Tahara E (1990) Growth factors and oncogenes in human gastrointestinal carcinomas. J Cancer Res Clin Oncol 116:121–131

    Google Scholar 

  • UICC (1987) TNM classification of malignant tumors, 4th edn Springer, Berlin Heidelberg New York

    Google Scholar 

  • Valen B, Viste A, Haugstvedt T, Eide GE, Soreide O, Members of the Norwegian Stomach Cancer Trial (1988) Treatment of stomach cancer, a national experience. Br J Surg 75:708–712

    Google Scholar 

  • Verschueren RJC, Willense PHB, Sleijfer DTH, Vries EGE de, Mulder HH (1988) Combined chemotherapeutic-surgical approach of locally advanced gastric cancer (abstract). Proc Am Soc Clin Oncol 7:93

    Google Scholar 

  • Wilke H, Preusser P, Fink U, Gunzer U, Meyer HJ, Meyer J, Siewert JR, Achterrath W, Lenaz L, Knipp H, Schmoll HJ (1989) Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 7:1318–1326

    Google Scholar 

  • Wilke H, Preusser P, Fink U, Achterrath W, Meyer HJ, Stahl M, Lenaz L, Siewert JR, Geerlings H, Köhne-Wömpner CH, Harstrick A, Schmoll HJ (1990a) New developments in the treatment of gastric carcinoma. Semin Oncol 17 [Suppl 2]:61–70

    Google Scholar 

  • Wilke H, Preusser P, Fink U, Achterrath W, Lenaz L, Stahl M, Schober C, Link H, Meyer HJ, Lucke B, Schmoll HJ (1990b) High dose folinic acid/etoposide/5-fluorouracil in advanced gastric cancer — a phase II study in elderly patients or patients with cardiac risk. Invest New Drugs 8:65–70

    Google Scholar 

  • Wilke H, Preusser P, Stahl M, Harstrick A, Meyer HJ, Achterrath W, Schmoll HJ, Seeber S (1991) Etoposide, folinic acid, and 5-fluorouracil in carboplatin-pretreated patients with advanced gastric cancer. Cancer Chemother Pharmacol 29:83–84

    Google Scholar 

  • Wils J, Bleiberg H (1989) Current status of chemotherapy for gastric cancer. Eur J Clin Oncol 25:3–8

    Google Scholar 

  • Wils J, Bleiberg H, Blijham G (1986) An EORTC gastrointestinal group evaluation of the combination of sequential methotrexate (MTX) and 5-fluorouracil (F), combined with adriamycin (A) (FAMTX) in advanced measurable gastric cancer. J Clin Oncol 4:1799–1803

    Google Scholar 

  • Wils JA, Klein HO, Wagener DJT, Bleiberg H, Reis H, Korsten F, Conroy T, Fickers M, Leyvraz S, Buyse M, Duez N for the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group (1991) Sequential high-dose methotrexate and fluorouracil combined with doxorubicin — a step ahead in the treatment of advanced gastric cancer: a trial the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 9:827–831

    Google Scholar 

  • Yamazaki H, Oshima A, Murakami R, Endoh S, Ubukata T (1989) A long-term follow-up study of patients with gastric cancer detected by mass screening. Cancer 63:613–617

    Google Scholar 

  • Zacho A, Cederqvist C, Fischerman K (1974) Surgical treatment of gastric malignancies. Ann Surg 179:94–191

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinic for Abdominal and Transplantation Surgery, Medical School Hamnnover, Konstanty-Gutschow-Str. 8, W-3000, Hannover 61, Germany

    H. J. Meyer & J. Jähne

  2. Department of Internal Medicine, University Essen, Hufelandstr. 55, W-4300, Essen, Germany

    H. Wilke

Authors
  1. H. J. Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Jähne
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Wilke
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

The “Journal of Cancer Research and Clinical Oncology” publishes in loose succession “Editorials” and “Guest editorials” on current and/or controversial problems in experimental and clinical oncology. These contributions represent exclusively the personal opinion of the author.

Multimodality treatment results were obtained by the Multidisciplinary Gastric Cancer Study Group: P. Preusser, B. Reers, H. Bünte (Department of Surgery, University Muenster), H. Knipp, H. J. Schmoll (Department of Hematology and Oncology, Medical School Hannover), U. Fink, J. R. Siewert (Department of Surgery, Technical University Muenchen), A. Weimann, R. Pichlmayr (Clinic for Abdominal and Transplantation Surgery, Medical School Hannover)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meyer, H.J., Jähne, J. & Wilke, H. Perspectives of surgery and multimodality treatment in gastric carcinoma. J Cancer Res Clin Oncol 119, 384–394 (1993). https://doi.org/10.1007/BF01218419

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01218419

Key words

Search

Navigation